Brief: Hls Therapeutics Announces Q1 Fiscal 2023 Financial Results
May 11 (Reuters) - Hls Therapeutics Inc HLS.TO :
* HLS THERAPEUTICS ANNOUNCES Q1 FISCAL 2023 FINANCIAL
RESULTS
* APPOINTED CRAIG MILLIAN AS CHIEF EXECUTIVE OFFICER OF
COMPANY
* Q1 2023 REVENUE WAS $14.8 MILLION COMPARED TO $14.6
MILLION
* NET LOSS FOR Q1 2023 WAS ($0.18) PER SHARE
Source text for Eikon: ID:nCNWlRYqpa
Further company coverage: HLS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HLS Therapeutics
See all newsBrief: Hls Therapeutics Increases Normal Course Issuer Bid
Brief: HLS Therapeutics Announces Q2 2026 Financial Results
Canada's HLS Therapeutics Q2 revenue rises on higher cardiovascular drugs demand
Brief: HLS Therapeutics - Secures Nilemdo Reimbursement With Private Payers Covering 80% Of Privately Insured Canadians
Canada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group